Evidence map›Paper›PMID 22768240›Full record

ArticlePloS one2012

miRNA-mRNA correlation-network modules in human prostate cancer and the differences between primary and metastatic tumor subtypes.

Wensheng Zhang, Andrea Edwards, Wei Fan, Erik K Flemington, Kun Zhang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. A review on methods for predicting miRNA-mRNA regulatory modules.Journal of integrative bioinformatics · 2022
    Review
  4. Article
  5. Using microRNA Networks to Understand Cancer.International journal of molecular sciences · 2018
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Wensheng ZhangDepartment of Computer Science, Xavier University of Louisiana, New Orleans, Louisiana, United States of America.
Andrea Edwards
Wei Fan
Erik K Flemington
Kun Zhang
Xavier University of Louisiana · USTulane University · US

Funding

STABILITY' (symptomatic review during biologic therapy) Review in Inflammatory Bowel DiseaseP20GM103424 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI Seetharama D Jois · 2012 to 2026
$57.4M
XAVIER'S RCMI CANCER RESEARCH PROGRAMG12RR026260 · NCRR · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE · 2009 to 2011
$7.0M
Intercellular communication in Epstein Barr virus reactivationR01AI101046 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2012 to 2016
$1.9M
Role of the cellular microRNA, miR-155, in EBV type III latency signalingR01CA138268 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA138268NCRR NIH HHS 5G12RR026260-03NCRR NIH HHS G12 RR026260NIAID NIH HHS R01 AI101046NIGMS NIH HHS P20 GM103424NIGMS NIH HHS P20GM103424
6 · The paper itself

Abstract

Recent studies have shown the contribution of miRNAs to cancer pathogenesis. Prostate cancer is the most commonly diagnosed cancer in men. Unlike other major types of cancer, no single gene has been identified as being mutated in the majority of prostate tumors. This implies that the expression profiling of genes, including the non-coding miRNAs, may substantially vary across individual cases of this cancer. The within-class variability makes it possible to reconstruct or infer disease-specific miRNA-mRNA correlation and regulatory modular networks using high-dimensional microarray data of prostate tumor samples. Furthermore, since miRNAs and tumor suppressor genes are usually tissue specific, miRNA-mRNA modules could potentially differ between primary prostate cancer (PPC) and metastatic prostate cancer (MPC). We herein performed an in silico analysis to explore the miRNA-mRNA correlation network modules in the two tumor subtypes. Our analysis identified 5 miRNA-mRNA module pairs (MPs) for PPC and MPC, respectively. Each MP includes one positive-connection (correlation) module and one negative-connection (correlation) module. The number of miRNAs or mRNAs (genes) in each module varies from 2 to 8 or from 6 to 622. The modules discovered for PPC are more informative than those for MPC in terms of the implicated biological insights. In particular, one negative-connection module in PPC fits well with the popularly recognized miRNA-mediated post-transcriptional regulation theory. That is, the 3'UTR sequences of the involved mRNAs (∼620) are enriched with the target site motifs of the 7 modular miRNAs, has-miR-106b, -191, -19b, -92a, -92b, -93, and -141. About 330 GO terms and KEGG pathways, including TGF-beta signaling pathway that maintains tissue homeostasis and plays a crucial role in the suppression of the proliferation of cancer cells, are over-represented (adj.p<0.05) in the modular gene list. These computationally identified modules provide remarkable biological evidence for the interference of miRNAs in the development of prostate cancers and warrant additional follow-up in independent laboratory studies.

Indexed as

AlgorithmsCluster AnalysisGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMaleMicroRNAsNeoplasm MetastasisProstatic NeoplasmsRNA, MessengerSignal TransductionTranscription, GeneticTransforming Growth Factor betaMicroRNAsRNA, MessengerTransforming Growth Factor beta

Identifiers

PMID22768240
PMCPMC3387006
OpenAlexW1982297646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.